May 6, 2020
Nanobiotix’s Phase 1 trial in pancreatic cancer safe to proceed (FDA)
another step forward for NBTXR3 activated by radiation therapy
Pharmaceuticals, Biotechnology and Life Sciences
Tag: NBTXR3
September 18, 2019
Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis
Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer.
October 21, 2016
Nanobiotix’s partner, PharmaEngine launched a new NBTXR3 clinical trial in head and neck cancers
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.